Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€104.10

€104.10

-7.220%
-8.1
-7.220%
€160.00

€160.00

 
18.09.24 / Tradegate WKN: A2PSR2 / Name: BioNTech / Stock / Mid Cap /
Latest predictions
€360.00
16.09.24
-8.52%
buy
16.09.24
-4.67%
buy
16.09.24
-4.93%
buy
16.09.24
-4.06%
buy
€180.00
15.09.24
-5.36%
buy
15.09.24
-5.36%
buy
Best running prediction
€130.00
13.10.21
-50.76%
Your prediction

BioNTech SE ADR Stock

BioNTech SE ADR took a tumble today and lost -€8.100 (-7.220%).
The stock is one of the favorites of our community with 21 Buy predictions and 3 Sell predictions.
With a target price of 160 € there is a hugely positive potential of 53.7% for BioNTech SE ADR compared to the current price of 104.1 €.
Our community identified positive and negative aspects for BioNTech SE ADR stock for the coming years. 31 users see the criterium "Worthwhile Investment for the next years" as a plus for the BioNTech SE ADR stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.

Pros and Cons of BioNTech SE ADR in the next few years

Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

When evaluating the financials of BioNTech, a company well-known for its innovative approach in the biotechnology industry, a mixed perspective emerges. Recent years have seen substantial growth and the broadening of its operational landscape, particularly accentuated by the global health crisis precipitated by the COVID-19 pandemic. However, the financial statements reflect complexities, indicating both potential and significant challenges that investors should ponder carefully.

Strong Income Generation: For the year ending 2023, BioNTech reported a net income of €930.3 million, showcasing its capability to generate substantial profit despite a competitive market landscape. This ability to translate sales into profit is crucial for any business, and with ongoing demand for vaccine technologies, this income could provide a sustainable path forward.

Robust Balance Sheet: An impressive total asset figure of €23 billion as of December 31, 2023 highlights BioNTech's strong market position. Importantly, cash reserves stand at €11.66 billion, which not only underscores liquidity but also positions the company well for future investments or R&D expenditures.

Comments

Prediction Buy
Perf. (%) 3.38%
Target price 170.000
Change
Ends at 17.12.22

Target price set to 170.0
Show more

Buy BioNTech SE ADR
Show more

Buy BioNTech SE ADR
Show more